Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2014 May;58(9):1297-307.
doi: 10.1093/cid/ciu046. Epub 2014 Jan 22.

Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials

Jean B Nachega  1 , Jean-Jacques Parienti, Olalekan A Uthman, Robert Gross, David W Dowdy, Paul E Sax, Joel E Gallant, Michael J Mugavero, Edward J Mills, Thomas P Giordano
Affiliations
Meta-Analysis

Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials

Jean B Nachega et al. Clin Infect Dis. 2014 May.

Abstract

Background: Contemporary antiretroviral treatment regimens are simpler than in the past, with lower pill burden and once-daily dosing frequency common. We performed a meta-analysis of randomized controlled trials (RCTs) to investigate the impact of pill burden and once-daily vs twice-daily dosing on ART adherence and virological outcomes.

Methods: A literature search of 4 electronic databases through 31 March 2013 was used. RCTs comparing once-daily vs twice-daily ART regimens that also reported on adherence and virological suppression were included. Study design, study population characteristics, intervention, outcome measures, and study quality were extracted. Study quality was rated using the Cochrane risk-of-bias tool.

Results: Nineteen studies met our inclusion criteria (N = 6312 adult patients). Higher pill burden was associated with both lower adherence rates (P = .004) and worse virological suppression (P < .0001) in both once-daily and twice-daily subgroups, although the association with adherence in the once-daily subgroup was not statistically significant. The average adherence was modestly higher in once-daily regimens than twice-daily regimens (weighted mean difference = 2.55%; 95% confidence interval [CI], 1.23 to 3.87; P = .0002). Patients on once-daily regimens did not achieve virological suppression more frequently than patients on twice-daily regimens (relative risk [RR] = 1.01; 95% CI, 0.99 to 1.03; P = .50). Both adherence and viral load suppression decreased over time, but adherence decreased less with once-daily dosing than with twice-daily dosing.

Conclusions: Lower pill burden was associated with both better adherence and virological suppression. Adherence, but not virological suppression, was slightly better with once- vs twice-daily regimens.

Keywords: ART; fixed-dose combination; once-daily; randomized controlled trials; twice-daily.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Study selection flow diagram. Abbreviations: QD, once daily; RCT, randomized controlled trial; TID, three times a day.
Figure 2.
Figure 2.
Antiretroviral therapy adherence rate, virological response, and pill burden. Area of circle is proportional to the sample size. Blue, once-daily regimens; orange, twice-daily regimens.
Figure 3.
Figure 3.
Forest plot of the effect of once-daily vs twice-daily antiretroviral regimens on the rate of adherence. Abbreviations: CI, confidence interval; IV, inverse variance; SD, standard deviation.
Figure 4.
Figure 4.
Forest plot of the effect of once-daily vs twice-daily antiretroviral regimens on virologic suppression (plasma RNA HIV level <50 or <200 copies/mL). Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; M-H, Mantel-Haenszel.
See this image and copyright information in PMC

Comment in

References

    1. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15:1181–3. - PubMed
    1. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med. 2007;146:564–73. - PubMed
    1. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350×10(9) cells/L. Ann Intern Med. 2003;139:810–6. - PubMed
    1. Nachega JB, Mugavero MJ, Zeier M, Vitoria M, Gallant JE. Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs. Patient Prefer Adherence. 2011;5:357–67. - PMC - PubMed
    1. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. New Engl J Med. 2006;354:251–60. - PubMed

Publication types

Substances